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ABSTRACT
Interferons (IFNs) are key regulators of a number of inflammatory conditions in which neutrophils
play an important role in pathology, such as rheumatoid arthritis (RA) and systemic lupus
erythematosus (SLE), where Type I IFNs are implicated in disease pathology. However, IFNs are
usually generated in vivo together with other cytokines that also have immunoregulatory functions
but such interactions are poorly-defined experimentally. We measured the effects of Type-I IFN
(IFNα), elevated in both RA and SLE, on the functions of healthy neutrophils incubated in vitro
in the absence and presence of pro-inflammatory cytokines typically elevated in inflammatory
diseases (TNFα, GM-CSF). IFNα alone had no effect on neutrophil apoptosis, however it did
abrogate the anti-apoptotic effect of GM-CSF (18h, p< 0.01). The enhanced stabilty of the
anti-apoptotic protein Mcl-1 and delayed activation of caspase activation normally regulated by
GM-CSF were blocked by IFNα: this effect was mediated, in part, by activation of p38 MAPK,
increased turnover of the anti-apoptotic protein Mcl-1 and cleavage of caspases. IFNα alone
also primed ROS production alone and maintained the transient priming effect of TNF for up to
4h: it also down-regulated GM-CSF and TNFα-activated expression of CXCL1, CXCL2, CXCL3,
CXCL8, CCL3 and CCL4, but in contrast increased the expression of CXCL10. These novel data
identify complex regulatory signalling networks in which Type I IFNs profoundly alter the response
of neutrophils to inflammatory cytokines. This is likely to have important consequences in vivo
and may explain the complexity and heterogeneity of inflammatory diseases such as RA, in which
multiple cytokine cascades have been activated.
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1 INTRODUCTION
Interferons (IFNs) are a family of cytokine
glycoproteins that regulate the immune response to
infection by bacteria, viruses and parasites and are
broadly grouped into Type-I, -II and -III, based on
their receptor signalling (Platanias, 2005; Li et al.,
2009). Type-I IFNs, including IFNα, IFNβ, IFN,
IFNκ and IFNω, signal through the IFNα receptor
dimer (IFNAR1 and IFNAR2), whereas Type-II
IFN, IFNγ, signals via the IFNγ receptor dimer
(IFNGR1 and IFNGR2) (Platanias, 2005). Type-
III IFNs, IFNλ1, IFNλ2, IFNλ3 (also known as
IL29, IL28α and IL28β, respectively) signal via a
receptor complex comprising IL10R2 and IFNLR1
(Li et al., 2009). Interferon receptors signal through
the Janus Kinase (JAK) family of enzymes (JAK1,
JAK2, JAK3, Tyk2), which, when activated, induce
phosphorylation and nuclear translocation of signal
transducer and activation of transcription (STAT)
proteins (Platanias, 2005; Li et al., 2009; O’Shea
and Plenge, 2012). Type-I interferons activate
heterodimers of JAK1:Tyk2 via activation of the
IFNα receptor complex leading to activation of
STAT1:STAT2 heterodimers. In some instances,
Type-I interferons can also activate STAT3, STAT4
and STAT5 (Platanias, 2005). Type-II interferons
activate heterodimers of JAK1:JAK2 leading to
activation of STAT1 homodimers.
As well as playing key roles in the host response
to pathogen-mediated infections, IFNs are also
implicated in the pathogenesis of a number of
inflammatory disorders, including rheumatoid
arthritis (RA), systemic lupus erythematosus (SLE),
Sjo¨grens syndrome and myositis (Wright et al.,
2014; Higgs et al., 2012; Peck and Nguyen, 2012).
In SLE, Type-I interferon signalling correlates
with disease severity, and may reflect activation
of plasmacytoid dendritic cells (pDCs) which
contribute to auto-antibody formation in this disease
(Lichtman et al., 2012; Lande et al., 2011). However,
the role of IFNs in RA is less well understood
and TNFα has generally been considered to
be the predominant cytokine that drives disease
progression, based on the success of therapeutic
TNFα blockade (TNFi) (Hyrich et al., 2009, 2006).
However, there are several reports of an interferon
gene expression signature in RA peripheral blood
(Raterman et al., 2012; Reynier et al., 2011; van
Baarsen et al., 2010; Mavragani et al., 2010), and
we recently identified a correlation between a Type-
I ‘IFN-high’ gene expression signature in peripheral
blood neutrophils and good response to TNFi in a
cohort of RA patients with severe disease activity
(Wright et al., 2014, 2017). As TNFα inhibits the
activity of pDCs and thereby the production of
IFNα (Palucka et al., 2005), it appears paradoxical
that patients who respond to TNFi therapy have
high levels of interferon-regulated gene activity.
However, whilst TNFα can often be detected at
high levels in RA synovial fluid (Wright et al.,
2012), concentrations of TNFα in RA serum are
typically low or even undetectable, even in patients
who subsequently respond well to TNFi therapy
(Wright et al., 2012, 2011).
The effect of Type-II IFN (IFNγ) alone on
neutrophils has been relatively well defined, and
in vitro can enhance expression of the high-affinity
cell-surface molecules FcγRI (CD64) (Quayle et al.,
1997) and MHC-II (Cross et al., 2003), both
of which can be detected on the surface of ex
vivo neutrophils isolated from RA synovial fluid
(Quayle et al., 1997; Cross et al., 2003). IFN-γ
also delays neutrophil apoptosis and primes the
respiratory burst (Sakamoto et al., 2005; Klebanoff
et al., 1992). However, the effect of Type-I IFNs
on neutrophil function is less clear, with studies
reporting contradictory effects on both apoptosis
and reactive oxygen species (ROS) production via
the respiratory burst (Sakamoto et al., 2005; Koie
et al., 2001; Conde et al., 1994).
The aim of this study was to characterise the
functional effects of Type-I interferon (IFNα) on
healthy neutrophils, in the absence and presence
of GM-CSF and TNFα, cytokines typically
elevated in RA. We demonstrate that co-incubation
of healthy neutrophils with IFNα profoundly
alters their functional responses in ways that
have important consequences for understanding
neutrophil phenotype in inflammatory disease.
These data reveal potential complex regulatory
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cytokine-signalling networks that control immune
function in inflammation and inflammatory disease.
2 METHODS
2.1 Isolation of neutrophils
Participants gave written informed consent according
to the declaration of Helsinki and thics approval
for this study was obtained from the University
of Liverpool Committee on Research Ethics.
Neutrophils (purity > 97%, viability > 98%)
were isolated from healthy heparinised peripheral
blood using HetaSep (Stem Cell) and Ficoll-Paque
(GE Healthcare), and contaminating erythrocytes
were removed by hypotonic lysis as described
previously (Wright et al., 2013). Freshly-isolated
neutrophils were suspended at 106 or 5x106
cells/mL in RPMI media (containing 10% human
AB serum (Sigma)) and incubated at 37◦C and
5% CO2 for up to 18h. Cytokines were added at
the following concentrations: GM-CSF (5 ng/mL,
Roche), TNF (10 ng/mL, Calbiochem), IFNαA2
(0.1-20 ng/mL, Sigma), IFNβ1a (0.1-20 ng/mL,
ImmunoTools). Preliminary experiments showed
similar results using both Type-I IFNs (IFNαA2 and
IFNβ1a), therefore IFNαA2 was used throughout
and is referred to in the text as IFNα. Inhibitors
of cell signalling were added 30 min prior to
cytokine stimulation: BIRB796 (10µM, p38 MAPK
inhibitor, Tocris), PD98059 (50µM, ERK1/2
inhibitor, Merck), JNK-IN-8 (1µM, JNK inhibitor,
Selleck Chemicals). Cycloheximide (inhibitor of
protein synthesis) was used at 10µg/mL (Sigma)
and added 30 min prior to cytokine treatment of
neutrophils.
2.2 Measurement of apoptosis
Neutrophils (2.5x104) were diluted in 50µL of
HBSS (Gibco) containing 0.5µL Annexin V-FITC
(Invitrogen), and incubated in the dark at room
temperature for 15 min. The total volume was
then made up to 250µL with HBSS containing
propidium-iodide (PI, 1µg/mL) before analysis by
flow cytometry (5,000 events analysed) using a
Guava EasyCyte instrument.
2.3 qPCR
RNA was extracted using Trizol (Life Technologies)
and chloroform, precipitated in isopropanol and
cleaned using the RNeasy kit (Qiagen) including a
DNase digestion step. cDNA was synthesised using
the Superscript III First Strand cDNA Synthesis
kit (Invitrogen) using equal concentrations of
RNA across samples, as per the manufacturer’s
instructions. Real-time PCR analysis was carried
out using the QuantiTect SYBR Green PCR kit
(Qiagen) as per the manufacturer’s instructions.
Analysis was carried out on a Roche 480
LightCycler in a 96-well plate using a 20µL reaction
volume. Primers used are shown in Table 1.
Target gene expression was quantified against B2M
as a housekeeping gene (Zhang et al., 2005; Pfaffl,
2001). We also carried out an RNA-seq experiment
(n=1) to identify targets for validation by qPCR and
Western blot. This was carried out using standard
RNA-seq protocols on the Illumina HiSeq 2000
platform as previously described (Wright et al.,
2017, 2013, 2015).
2.4 Western blotting
Neutrophils were rapidly lysed in boiling Laemmli
buffer containing phosphatase inhibitors (Calbiochem).
Proteins were separated by SDS-PAGE on a
12% gel and transferred onto PVDF membrane
(Millipore). Primary antibodies were: Mcl-1
(1:1000, Cell Signalling), caspase-8 (1:1000, Cell
Signaling) caspase-9 (1:1000, Cell Signaling),
phosphorylated p38 MAPK (1:1000, Cell Signaling),
total p38 MAPK (1:1000, Cell Signaling) Actin
(1:10,000, Abcam). Secondary antibodies were
anti-rabbit IgG (GE Healthcare) and anti-mouse
IgG (Sigma) HRP-linked antibodies (1:10,000).
Bound antibodies were detected using the ECL
system (Millipore) on carefully-exposed film to
avoid saturation (Amersham).
2.5 Measurement of respiratory burst
Neutrophils (5x106/mL) were incubated for up to
4h with IFNα (10 ng/mL) in the absence or presence
of GM-CSF (5 ng/mL), or TNFα (10 ng/mL). Cells
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CXCL1 F-‘TGGCTTAGAACAAAGGGGCTTA’ R-‘AAAGGTAGCCCTTGTTTCCC’
CXCL2 F-‘TTTCACAGTGTGTGGTCAACAT’ R-‘ACACAGAGGGAAACACTGCATA’
CXCL3 F-‘ACCGAAGTCATAGCCACACTC’ R-‘ACGCTGATAAGCTTCTTACTTCT’
CCL3 F-‘GCTCTCTGCAACCAGTTCTCT’ R-‘TGGCTGCTCGTCTCAAAGTAG’
CCL4 F-‘GCTGTGGTATTCCAAACCAAAAGAA’ R-‘AGGTGACCTTCCCTGAAGACT’
CXCL8 F-‘AAAAGCCACCGGAGCACTCCAT’ R-‘AGAGCCACGGCCAGCTTGGA’
CXCL10 F-‘CCACGTGTTGAGATCATTGCT’ R-‘TGCATCGATTTTGCTCCCCT’
B2M F-‘ACTGAATTCACCCCCACTGA’ R-‘CCTCCATGATGCTGCTTACA’
Table 1. Primers used in qPCR experiments.
(2x105) were diluted in HBSS containing luminol
(10µM) and the respiratory burst stimulated with
f-Met-Leu-Phe (fMLP) (1µM). Luminescence was
measured, in duplicate, continuously for 30 min.
2.6 Statistical analysis
Statistical analysis was carried out using SPSS v20,
using the Student’s t-test unless otherwise stated.
3 RESULTS
3.1 Interferon alpha abrogates GM-CSF
delayed neutrophil apoptosis via p38
MAPK signalling
Blood neutrophils constitutively undergo apoptosis
after around 24h but during inflammation, apoptosis
can be delayed by cytokines such as TNFα and GM-
CSF (Wright et al., 2013). In order to determine
the effect of IFNα on neutrophil apoptosis, healthy
neutrophils were incubated for 18h in the absence
or presence of IFNα over a range of concentrations.
IFNα alone did not significantly alter the rate of
constitutive neutrophil apoptosis (Figure 1A), but
it dose-dependently abrogated GM-CSF-delayed
apoptosis (Figure 1A, p< 0.05). However, this
effect was cytokine-specific as it had no significant
effect on the rate of apoptosis in neutrophils treated
for 18h with TNFα (Figure 1B). In order to explore
the mechanisms responsible for the effect of IFNα
on GM-CSF-delayed apoptosis, neutrophils were
incubated for up to 18h with these cytokines and
protein lysates were analysed by Western blot. GM-
CSF has previously been shown to delay neutrophil
apoptosis through stabilisation of the anti-apoptotic
protein Mcl-1 (Derouet et al., 2004). We found
that the levels of Mcl-1 after 6h incubation were
significantly lower in neutrophils treated with GM-
CSF and IFNα compared to GM-CSF alone (Figure
1C,D, p< 0.05). IFNα treatment alone had no
significant effect on Mcl-1 levels compared to
untreated controls (data not shown). Overnight
incubations (18h) of neutrophils treated with GM-
CSF and IFNα had significantly lower levels of
pro-caspase-8 and pro-caspase-9 in the presence of
IFNα compared to GM-CSF alone (Figure 1E-G,
p< 0.05).
Mcl-1 is an anti-apoptotic, Bcl-2 family protein and
a key regulator of neutrophil apoptosis (Moulding
et al., 1998; Wardle et al., 2011). It is rapidly
turned over in human neutrophils and cellular
expression of Mcl-1 correlates with the level of
neutrophil apoptosis. However, Mcl-1 levels can
be maintained (and apoptosis delayed) either by
phosphorylation and stabilisation of existing Mcl-1
protein or synthesis of new Mcl-1 protein (Derouet
et al., 2004). Pre-incubation of neutrophils with
cycloheximide (CHX), an inhibitor of protein
synthesis, prior to addition of GM-CSF and IFNα
showed that levels of Mcl-1 protein decreased more
rapidly in the presence of GM-CSF and IFNα
compared to GM-CSF alone (Figure 2A). This
suggests that IFNα blocks the stabilisation of Mcl-
1, likely via interference with post-translational
modification (phosphorylation) of mature Mcl-1
protein (Thomas et al., 2010). IFNα alone had
no effect on Mcl-1 levels in the presence of CHX
(Figure 2A).
We next investigated the potential mechanism by
which IFNα abrogates the anti-apoptotic effect
of GM-CSF using signalling inhibitors of p38
MAPK, JNK and ERK1/2 which are known down-
stream targets of the IFNAR1/2 complex (Platanias,
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Figure 1. The effect of IFNα on neutrophil apoptosis. (A) IFNα (IFNA) alone had no effect on neutrophil
apoptosis over a range of physiologically-relevant concentrations (0.1-20 ng/mL) compared to untreated
neutrophils (VC, vehicle control) at 18h. However, IFNα abrogated the anti-apoptotic effect of GM-CSF
(5ng/mL). (B) IFNα had no effect on the anti-apoptotic effect of TNFα (TNF). (C,D) Expression of Mcl-1
was lower in neutrophils co-incubated with GM-CSF and IFNα compared to GM-CSF alone. (E-G) The
levels of pro-caspase-8 and -9 were lower after 18h culture in the presence of GM-CSF and IFNα compared
to GM-CSF alone. (all experiments n=3, *p< 0.05, **p< 0.01).
2005). Whilst JNK and ERK1/2 were rapidly
activated by IFNα in the absence and presence of
GM-CSF, inhibition of JNK and ERK1/2 (using
JNK-IN-8 and PD98059 respectively) had no
significant effect on neutrophil apoptosis (data not
shown). However, IFNα significantly altered the
phosphorylation kinetics of p38 MAPK (Figure
2B), and inhibition of all isoforms of p38 MAPK
by BIRB796 significantly decreased the abrogative
effect of IFNα on GM-CSF-delayed apoptosis by
around 25% (Figure 2C, p< 0.05).
3.2 Interferon alpha primes the
neutrophil respiratory burst and
enhances TNF-priming
The production of reactive oxygen species (ROS)
via the respiratory burst is rapidly triggered
by the phagocytosis of bacteria (Wright et al.,
2010). However, in inflammatory diseases such
as RA, inappropriate secretion of ROS along with
proteolytic enzymes can induce damage to the
surface of the joints and degrade cartilage (Wright
et al., 2014, 2010). Using luminol-enhanced
chemiluminescence, we found that neutrophil ROS
production in response to fMLP was not primed
by 1h treatment with IFNα (Figure 3A). However,
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Figure 2. The effect of IFNα on Mcl-1 turnover and p38 MAPK activation. (A) Pre-incubation of
neutrophils with cycloheximide (CHX) prior to GM-CSF and IFNα showed increased turnover of Mcl-1
protein levels in the presence of IFNα, likely through blockade of Mcl-1 protein stabilisation. (B) p38
MAPK was rapidly phosphorylated by IFNα over 120 min in the absence and presence of GM-CSF. (C)
Inhibition of p38 MAPK phosphorylation by BIRB796 significantly inhibited the abrogative effect of IFNα
on GM-CSF-delayed neutrophil apoptosis over 18h (n=4, *p< 0.05, n.s. = not significant).
ROS production was significantly increased by pre-
treatment with IFNα for 3h and then stimulated
by fMLP (Figure 3B). Co-incubation of IFNα with
GM-CSF had no significant effect on the GM-CSF-
primed respiratory burst, which was sustained over
a 5h incubation period (4h timepoint shown in
Figure 3C). TNFα rapidly primed the neutrophil
respiratory burst over short incubation times of up
to 1h (data not shown), but by 4h this priming
effect was lost. However, co-incubation with IFNα
significantly sustained this transient priming effect
of TNFα over and above the priming effect of the
IFNα alone (Figure 3D).
3.3 Interferon alpha is a key regulator of
neutrophil chemokine production
Neutrophils play an important role in the crosstalk
between the innate and adaptive immune system
via the secretion of chemokines (Mantovani et al.,
2011). We measured the expression of chemokines
by healthy neutrophils in response to incubation
for 1h with GM-CSF and TNFα in the absence
and presence of IFNα using RNA-Seq (n=1, data
not shown) and from these data, we selected a
panel of genes that were subsequently analysed by
qPCR (n=3). GM-CSF and TNFα significantly up-
regulated the expression of CCL3, CCL4, CXCL1,
CXCL2, CXCL3 and CXCL8, but not CXCL10
(Figure 4A,B). IFNα alone significantly up-
regulated the expression of CXCL10 compared to
untreated neutrophils (> 600-fold, data not shown).
However, when neutrophils were co-incubated
with IFNα and GM-CSF or TNF, the increase
in expression of CCL3, CCL4, CXCL1, CXCL2,
CXCL3 and CXCL8 was significantly abrogated
(Figure 4C,D). Conversely, the expression of
CXCL10 was significantly enhanced (Figure 4C,D).
We next investigated chemokine expression in a
group of RA patients who had undergone whole
transcriptome sequencing as part of a previous study
(Wright et al., 2014). In this study, patients clustered
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Figure 3. Effect of IFNα on neutrophil respiratory burst. (A) IFNα (IFNA) did not prime the respiratory
burst in response to fMLP (1µM) after short incubation times of 1h, (B) but did significantly prime the
respiratory burst after 3h incubation. (C) Co-incubation of IFNα with GM-CSF had no effect on neutrophil
priming for up to 4h. (D) IFNα maintained TNF-induced priming for up to 4h incubation. Representative
traces from n=4 experiments (*p< 0.05, **p< 0.01).
into two groups with either ‘IFN-high’ or ‘IFN-
low’ gene expression profiles. When we analysed
gene expression levels for CCL3, CCL4, CXCL1,
CXCL2, CXCL3 and CXCL8 we found that these
were lower in the ‘IFN-high’ patients than in the
‘IFN-low’ patients (Figure 4E), mirroring the effect
we observed using qPCR of neutrophils treated in
vitro with IFNs in combination with TNFα and
GM-CSF. Interestingly, the expression of CXCL10
was higher in the ‘IFN-high’ patients than in the
‘IFN-low’ patients, confirming that the in vivo
phenotype of IFN-exposed neutrophils correlates to
that induced by in vitro exposure to IFNs. These
data imply that the in vitro regulatory effects of
IFNs on neutrophil function that we have observed
in this study, may also occur in vivo.
4 DISCUSSION
While the vast majority of in vitro experiments
characterise the effects of single pro-inflammatory
cytokines on immune cells, it is evident that
during inflammation in vivo, multiple cytokines
are involved in the regulation of immune function.
In this study, we have investigated the effect of
Type-I interferon (IFNα) on neutrophil functions in
the absence and presence of two pro-inflammatory
cytokines (GM-CSF, TNFα) that are implicated
in the pathogenesis of rheumatoid arthritis (RA)
(Wright et al., 2012). We have demonstrated that
IFNα profoundly alters the response of neutrophils
to these pro-inflammatory cytokines in ways that
have important implications for understanding
neutrophil phenotype in disease.
In our experiments, IFNα abrogated the anti-
apoptotic effect of GM-CSF, via blocking the
stabilisation of Mcl-1 protein and activation
of caspases. We found that IFNα altered the
phosphorylation kinetics of p38 MAPK, and that
blockade of p38 MAPK with a highly selective
inhibitor (BIRB796) significantly decreased the
effect of IFNα on GM-CSF-delayed apoptosis. p38
MAPK is a known regulator of Mcl-1 turnover in
neutrophils (Derouet et al., 2004), and inhibition
7
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Figure 4. Effect of IFNα on chemokine expression. Chemokine expression was upregulated in neutrophils
incubated for 1h with (A) GM-CSF or (B) TNFα (fold change in expression from 0h shown, n=3
experiments). Co-incubation with IFNα (IFN-A) abrogated the expression of chemokines in the presence
of (C) GM-CSF or (D) TNF, whereas expression of CXCL10 was enhanced (*p< 0.05, **p< 0.01). (E)
RA patients with an ‘IFN-high’ gene expression profile expressed chemokines (CXCL1, CXCL2, CXCL3,
CXCL8, CCL3, CCL4) at lower levels than ‘IFN-low’ RA patients (n=14) levels (fold difference in mean
expression level between the two groups of patients shown). The expression level of CXCL10 was higher
in ‘IFN-high’ RA patients than in ‘IFN-low’ patients.
of p38 MAPK using BIRB796 has previously been
shown to inhibit Mcl-1 degradation and induction
of apoptosis in myeloid cells induced by purvanalol
A, another molecule that can abrogate the anti-
apoptotic effect of GM-CSF (Phoomvuthisarn et al.,
2018). Sodium salicylate also abrogates GM-
CSF-delayed neutrophil apoptosis via p38 MAPK
signalling and Mcl-1 turnover mechanisms (Derouet
et al., 2004). Mcl-1 is an anti-apoptotic Bcl-2 family
protein that is a key regulator of neutrophil survival.
Activators of p38 MAPK signalling, such as vitamin
D, have been shown to have a pro-apoptotic effect
on neutrophils via regulation of expression of Bcl-
2 and caspase family member genes (Tang et al.,
2018; Yang et al., 2015). Whilst we saw changes
in the levels of Mcl-1, caspase-8 and caspase-9
protein in our experiments, we did not see any
change in expression of these genes in our RNA-
seq experiment (data not shown), suggesting the
effect of IFNα is post-translational. p38 MAPK has
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also been shown to be anti-apoptotic in neutrophils
via the regulation of caspase phosphorylation
and activation (Alvarado-Kristensson et al., 2004;
Aoshiba et al., 1999) and therefore there remain
subtleties in the IFNα activation of p38 MAPK
that have not been completely addressed in our
study. It is interesting to note that IFNα did not
alter the delay in apoptosis induced by TNFα
in our study. TNFα-delayed apoptosis in human
neutrophils is not dependent upon Mcl-1 levels or
stabilisation of Mcl-1 protein; this is mediated via
NF-κB activation and synthesis of the Bcl-2 family
protein A1/Bfl-1 (Cross et al., 2008).
IFNγ has previously been shown to prime the
neutrophil respiratory burst, but the role of IFNα
in this process is less clear, with conflicting reports
in the literature of the effect of IFNα on neutrophil
apoptosis and ROS production (Sakamoto et al.,
2005; Koie et al., 2001; Conde et al., 1994). This
may be due to the IFNα isoform that was used
in in vitro experiments. IFNα has 13 different
isoforms (Gibbert et al., 2013), and the isoform
used in our experiments was IFNαA2, which is
the most abundant isoform in humans. In addition,
inconsistencies in the measurement of IFNs as
units/mL rather than ng/mL, often makes direct
comparison of experimental conditions difficult.
We comprehensively showed that over incubations
of up to 1h IFNα was not able to prime the
respiratory burst. However, over longer incubations
> 3h, IFNα primed the respiratory burst, both
alone and in combination with TNFα. This may
indicate a requirement for gene expression and
a secondary, autocrine signalling effect to fully
initiate the primed response.
Our experiments also identified an important role
for IFNα in the regulation of chemokine production
by neutrophils. We showed that IFNα significantly
decreased the expression of chemokine genes
CXCL1, CXCL2, CXCL3, CCL3 and CCL4 in
response to GM-CSF and TNFα, but enhanced
the expression of CXCL10. This has important
implications for neutrophil-mediated regulation of
the immune response in vivo. The chemokines
CXCL1, CXCL2 and CXCL3 (GRO-α, -β and
–γ, respectively) and CCL3 and CCL4 (MIP-1α
and -1β, respectively) predominantly function as
neutrophil chemoattractants, whereas CXCL10
(IP-10) is primarily a chemoattractant for T-
cells, monocytes, NK cells and dendritic cells.
Therefore, the cellular signalling events regulated
by combinations of inflammatory cytokines (GM-
CSF and/or TNFα) and IFNs in vivo may act
as a switch to direct the immune response away
from neutrophil-mediated inflammation towards
lymphocyte-mediated inflammation, underlying the
key role of neutrophils in the cross-talk between the
innate and adaptive immune systems (Mantovani
et al., 2011). Importantly, we noted that the changes
in chemokine expression in the presence of IFNα
mirrored exactly the phenotype that is seen in
RA neutrophils, underlying the important role of
IFNα in the regulation and fine-tuning of neutrophil
function in inflammatory disease.
In summary, our data show that the response
of human neutrophils to TNFα and GM-
CSF is profoundly altered in vitro by IFNα,
whereby IFNα acts as a switch to alter the
inflammatory neutrophil phenotype by regulating
apoptosis, ROS release and chemokine production
This has important consequences for neutrophil
inflammatory responses in vivo, particularly in
complex and heterogeneous inflammatory diseases
such as RA in which combinations of these
cytokines exist, and may explain why some patients
respond better to certain biologic therapies than
others.
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